Is there a role for Elacestrant in ER+ metastatic breast cancer with ESR1-YAP1 fusion on NGS?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida
Answered on
It depends on the specific details of the fusion protein and where the fusion breakpoint is. Also, the clonality of the fusion may play a role too. There are reports of a stable in-frame ESR1 e6 YAP1 fusion protein that has the ESR1 DNA binding/nuclear localization domains but the ligand binding dom...
Join for free or sign in to see the full answer